Claims for Patent: 6,080,756

Summary for Patent: 6,080,756

Title:	Polymorphs of the prodrug 6-N-(L-ALA-L-ALA)-trovafloxacin
Abstract:	The invention relates to a monohydrate polymorph PII.M of a compound of the formula ##STR1## exhibiting the following X-ray powder diffraction pattern Peak No. 1 2 3 4 5 6 7 8 ______________________________________ 2-- θ-- (°) Cu 3.6 7.3 13.7 14.5 17.1 21.) 23.6 26.7 d space 24.2 12.2 6.5 6.1 5.2 4.2 3.8 3.3 ______________________________________ The invention also relates to methods of preparing the above compound, pharmaceutical compositions containing the above compound, and methods of treating bacterial infections by administering the above compound.
Inventor(s):	Timothy Norris, James J. McGarry, Douglas J. M. Allen
Assignee:	Pfizer Corp SRL
Application Number:	US09/011,370
Patent Claims:	1. A monohydrate polymorph PII.M of a compound of the formula ##STR6## exhibiting the following X-ray powder diffraction pattern ______________________________________ Peak No. 1 2 3 4 5 6 7 8 ______________________________________ 2.sub.-- θ.sub.-- (°) Cu 3.6 7.3 13.7 14.5 17.1 21.) 23.6 26.7 d space 24.2 12.2 6.5 6.1 5.2 4.2 3.8 3.3 ______________________________________ 2. A process for preparing prodrug polymorph monohydrate PII.M, of trovafloxacin, for the formula of claim 1, which comprises(a) preparing polymorph PII exhibiting the X-ray powder diffraction pattern ______________________________________ Peak no. 1 2 3 4 5 6 7 8 9 ______________________________________ 2.sub.-- θ.sub.-- 3.4 6.8 13.5 16.8 19.6 20.3 23.1 25.7 27.8 (°) Cu d space 26.0 13.1 6.6 5.3 4.5 4.4 3.8 3.5 3.2. ______________________________________ by treating the prodrug polymorph PI exhibiting the X-ray powder diffraction pattern. 3. The process of claim 2 step b) wherein said organic solvent is selected from the group consisting of (C1 -C6)alkyl esters of (C1 -C6)alkanoic acids and (C1 -C6)alkanols. 4. The process of claim 3 wherein said solvent is ethyl acetate. 5. A process for preparing prodrug polymorph monohydrate PII.M of claim 1 exhibiting the X-ray diffraction pattern described as follows: ______________________________________ Peak no. 1 2 3 4 5 6 7 8 ______________________________________ 2.sub.-- θ.sub.-- (°) Cu 3.6 7.3 13.7 14.5 17.1 21.0 23.6 26.7 d space 24.2 12.2 6.5 6.1 5.2 4.2 3.8 3.3 ______________________________________ which comprises treating the prodrug polymorph PI exhibiting the X-ray diffraction pattern described as follows: ______________________________________ Peak No. 1 2 3 4 5 6 7 8 ______________________________________ 2.sub.-- θ.sub.-- (°) 6.1 7.3 7.9 9.5 11.7 14.2 14.9 15.8 Cu d space 14.5 12.1 11.2 9.3 7.6 6.2 6.0 5.6 ______________________________________ Peak No. 9 10 11 12 13 14 ______________________________________ 2.sub.-- θ.sub.-- (°) 16.8 20.1 21.4 22.7 24.9 26.0 Cu d space 5.3 4.4 4.2 3.9 3.6 3.4 ______________________________________ with an organic solvent containing water. 6. The process of claim 5 wherein said organic solvent is a C1 -C6 alkyl ester of a C1 -C6 alkanoic acid or a C1 -C6 alkanol. 7. The process of claim 6 wherein said solvent is ethyl acetate. 8. A method for treating bacterial infection in a mammal in need thereof which comprises administering to said mammal a bacterial infection treating effective amount of the prodrug of claim 1. 9. A pharmaceutical composition for treating bacterial infection in a mammal comprising a bacterial infection treating effective amount of the prodrug of claim 1 and a pharmaceutically acceptable carrier. 10. The compound of claim 1 having a water content of about 2.7%.